Langerhans cells (LCs) are the antigen-presenting cells of the epithelial layer and are responsible for initiating immune responses against skin and mucosa-invading viruses. Human papillomavirus (HPV)-mediated suppression of LC function is a crucial mechanism of HPV immune evasion, which can lead to
persistent infection and development of several human
cancers, including cervical, anal, and head and
neck cancers. The cell-derived
cytokine-based biologic,
IRX-2, consists of multiple well-defined
cytokines and is broadly active on various immune cell subsets. In this study, we investigated primary human LC activation after exposure to HPV16, followed by treatment with
IRX-2 in vitro, and evaluated their subsequent ability to induce HPV16-specific T cells. In contrast to its activity on dendritic cells, HPV16 alone is not sufficient to induce phenotypic and functional activation of LCs. However,
IRX-2 induces a significant upregulation of antigen presentation and costimulatory molecules, T helper 1 (Th1)-associated
cytokine release, and
chemokine-directed migration of LCs pre-exposed to HPV16. Furthermore, LCs treated with
IRX-2 after HPV16 exposure induced CD8(+) T-cell responses against specific
HLA-A*0201-binding HPV16
T-cell epitopes. The present study suggests that
IRX-2 is an attractive
immunomodulator for assisting the immune response in eradication of HPV-infected cells, thereby potentially preventing HPV-induced
cancers.